Implementation of New Multimodal MRI Sequences by Fingerprint to Improve Ischemic Stroke Examination. (INDEX)

September 22, 2025 updated by: University Hospital, Grenoble

Implementation of New Multimodal MRI Sequences by Fingerprint to Improve Ischemic Stroke Examination, a Pilot Study and Proof of Concept

Currently, standard brain MRI takes 20 to 25 minutes, but in the case of ischemic stroke, every minute counts to limit the extension of the necrotic core, with the possibility of recanalizing the occluded artery (intravenous thrombolysis and/or mechanical thrombectomy).

The recent concept of MRI "Fingerprint" (Magnetic Resonance Fingerprinting, MRF) allows the production of a rapid single sequence and the extraction of numerous parameters.

Demonstrating the feasibility and interpretability of multimodal MRI images acquired in MRF would make it possible to consider implementing and, ultimately, replacing conventional sequences, with the aim of shortening acute stroke management times, increasing the number of sequences acquired within a short timeframe (by increasing informativeness), and thus improving patients' short and long-term vital and functional prognosis.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Grenoble, France, 38043
        • Chu Grenoble Alpes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age > 18 years
  • Subacute ischemic stroke patients (< 15 days after onset)
  • Middle cerebral artery or anterior cerebral artery territory stroke
  • Modified Rankin Scale (mRS) = 0-4

Exclusion Criteria:

* MRI contraindications

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental
Every patient will perform classic brain MRI with additional MRF sequences.
Device: Achieva 3.0T dStream Philips
Classic and MRF sequences will be carried out on the clinical machine (Achieva 3.0T dStream Philips) of the IRMaGe platform (CHUGA, Université Grenoble Alpes, Inserm, CNRS).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Success rate and interpretability of images acquired in MRF
Time Frame: From enrollment to the end of the MRI exam
Assessment of the success rate and interpretability (subjective evaluation with Likert scales of very satisfactory, satisfactory, insufficient, or unacceptable)
From enrollment to the end of the MRI exam

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Characterize and extract the physical parameters of the signal acquired with MRF.
Time Frame: From enrollment to the end of the MRI exam

Comparison of MRF imaging metrics: signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR), using mean values per ROI (region of interest).

Segmentation and comparison of lesions, with calculation of the Dice similarity coefficient and/or SSIM (Structural SIMilarity).

Visualization and description of artifacts encountered during acquisition (e.g., motion).

Quantification of delays:

Acquisition time: retrieval of raw data directly from MRI consoles. Reconstruction time: measurement of computation times. Extraction of information on cerebral microvas
From enrollment to the end of the MRI exam

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Grenoble

Collaborators

Grenoble Institut des Neurosciences

Investigators

  • Principal Investigator: Loïc LEGRIS, Dr, llegris@chu-grenoble.fr

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

February 14, 2024

First Submitted That Met QC Criteria

September 22, 2025

First Posted (Estimated)

September 30, 2025

Study Record Updates

Last Update Posted (Estimated)

September 30, 2025

Last Update Submitted That Met QC Criteria

September 22, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 38RC23.0410

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke, Ischemic

Clinical Trials on Achieva 3.0T dStream Philips

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe